Welcome!

News Feed Item

MiMedx at SAWC Spring 2014: Multiple Studies And Clinical Experience Demonstrate Clinical And Cost Effectiveness Of EpiFix Allograft For Treatment Of Hard-to-Heal Wounds

EpiFix® is shown to promote rapid healing and return to function for patients and provide a potential for significant cost savings.

MARIETTA, Ga., April 23, 2014 /PRNewswire/ -- EpiFix®, dehydrated human amnion/chorion membrane (dHACM) allografts, were shown to be clinically and cost effective in the treatment of multiple hard-to-treat wounds like diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers (PUs), according to data and case experiences being presented at the Spring Symposium on Advanced Wound Care, the leading national wound healing conference now in its 27th year.  The symposium begins today, April 23, 2014, and concludes on April 27, 2014.

"We are pleased that two abstracts highlighting EpiFix® allografts were selected for oral presentation and one of them, authored by Charles M. Zelen, DPM, FACFAS, FACFAOM, FAPWCA; Thomas E. Serena MD, FACS and Robert J. Snyder, DPM, MSc, CWS, was selected as 3rd place for Best Oral Abstract," said Parker H. "Pete" Petit, CEO of MiMedx Group, Inc.  (NASDAQ: MDXG).

"Clinically, EpiFix® is associated with more rapid healing and prevention of longer term complications including infection and amputation," said Dr. Stephen Bergquist, Medical Director for Jackson-Madison County Hospital.  "From the cost-of-care perspective, EpiFix requires the use of fewer grafts leading to overall cost savings," he continued.

Abstracts presenting EpiFix® studies and cases are:

  • A Prospective, Randomized, Comparative Study of Weekly vs. Bi-weekly Application of Dehydrated Human Amnion/Chorion Membrane Allograft in the Management of Diabetic Foot Ulcers (Abstract #CR_055, Zelen, Serena, Snyder) demonstrated in a 12-week study period of 40 patients with a mean time to complete healing of 2.4 weeks for weekly application of EpiFix® vs. 4.1 wks for biweekly application of EpiFix®.  This shows using EpiFix® weekly heals DFUs almost twice as fast as biweekly applications of EpiFix®. Overall complete heal rate with EpiFix® in both arms was 92.5% (37/40) at 12 weeks.

 

  • A Multi-center Randomized Controlled Clinical Trial Evaluating Two Application Regimens of Dehydrated Human Amniotic Membrane and Standard of Care vs. Standard of Care Alone in the Treatment of Venous Leg Ulcers (Abstract #CS_139,Serena,  Fetterolf , Harris, Doner, Patel, Connell, DeMarco, LE, McConnell , Lullove, Taffe.) 90 patients were enrolled to date in this ongoing trial. At time of interim analysis 68 patients had completed the study: 44 ulcers were randomized to receive dHACM (1 or 2 applications) and 24 received SOC alone. Outcomes were similar within the dHACM group.  At 4 weeks, 63.6% of wounds in the dHACM  group, and 25.0% of the standard of care group demonstrated greater than 40% wound closure at 4 weeks (p=0.0023). After 4 weeks ulcers treated with dHACM had reduced by 48.9% vs 12.0% for those treated with SOC only, p=0.003.

 

  • Treatment of Stage III and Stage IV Pressure Ulcers with Dehydrated Human Amnion/Chorion Membrane (Abstract #CS_014, Bergquist) evaluated the clinical and cost effectiveness of dHACM allografts as a treatment for Stage III and IV pressure ulcers (PUs).   In Stage III cases and Stage IV cases,  PUs of varying sizes were completely healed within weeks (from 1 week for  Stage III PUs with wound size of 8.6cm2 and 2.53 cm2, to 8 weeks for a Stage IV PU with an initial wound size of 9.2 cm2 ). Cost effectiveness of dHACM for treatment of PUs was influenced by increased healing rates, velocity of healing and subsequent reduction in risk for complications.  Wound size-appropriate grafts further reduce waste and cost per treatment. 

 

  • Human Amniotic Membrane Allograft to Treat Diabetic Foot Ulcers with Exposed Bone and Tendon   (Abstract# CS_117 Pougatsch, Shum, Belczyk, Rogers) 5 consecutive diabetic neuropathic patients exhibiting wounds with exposed bone and tendon were treated with EpiFix® with the intent to gain as much coverage over the exposed deep structures in as little time as possible in preparation for split-thickness skin grafting. All 5 patients had sufficiently developed granulation tissue overlying bone and tendon structures and were ready for split-thickness skin grafting in an average of 15 days (range 9-22). 4 patients healed the split-thickness skin grafts.

 

"These data support our previously published studies relating to the significant role for EpiFix® in advanced wound care," said Bill Taylor, President and COO of MiMedx. MiMedx is the leading developer and manufacturer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane.

MiMedx is exhibiting at the conference (booth 1506), and will host In-Booth Education with speakers Steve Bergquist, MD presenting on 'Complex wounds and pressure ulcer treatment with EpiFix', and Donna Becker, MSN, ACNP-BC who will discuss 'Clinical experiences with dHACM.'  Drs. Robert Snyder, Chuck Zelen, Matthew Garoufalis and Thomas Serena will be presenting about Wound Regeneration at a Company-sponsored symposium.

About EpiFix®

EpiFix® is a human amniotic allograft tissue offering uniquely processed through the Company's proprietary PURION® Process. EpiFix® dehydrated human amnion/chorion membrane (dHACM) can reduce inflammation and reduce scar tissue formation for enhanced healing. With a variety of sizes available, EpiFix® minimizes graft waste.  The Company's PURION® Process combines cleaning, dehydration and sterilization, making EpiFix® a safe, sterilized tissue that may be stored at ambient conditions for up to 5 years.

About MiMedx

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 225,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

SOURCE MiMedx Group, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The Founder of NostaLab and a member of the Google Health Advisory Board, John is a unique combination of strategic thinker, marketer and entrepreneur. His career was built on the "science of advertising" combining strategy, creativity and marketing for industry-leading results. Combined with his ability to communicate complicated scientific concepts in a way that consumers and scientists alike can appreciate, John is a sought-after speaker for conferences on the forefront of healthcare science,...
"We focus on SAP workloads because they are among the most powerful but somewhat challenging workloads out there to take into public cloud," explained Swen Conrad, CEO of Ocean9, Inc., in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"The Striim platform is a full end-to-end streaming integration and analytics platform that is middleware that covers a lot of different use cases," explained Steve Wilkes, Founder and CTO at Striim, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
The deluge of IoT sensor data collected from connected devices and the powerful AI required to make that data actionable are giving rise to a hybrid ecosystem in which cloud, on-prem and edge processes become interweaved. Attendees will learn how emerging composable infrastructure solutions deliver the adaptive architecture needed to manage this new data reality. Machine learning algorithms can better anticipate data storms and automate resources to support surges, including fully scalable GPU-c...
Predicting the future has never been more challenging - not because of the lack of data but because of the flood of ungoverned and risk laden information. Microsoft states that 2.5 exabytes of data are created every day. Expectations and reliance on data are being pushed to the limits, as demands around hybrid options continue to grow.
Your job is mostly boring. Many of the IT operations tasks you perform on a day-to-day basis are repetitive and dull. Utilizing automation can improve your work life, automating away the drudgery and embracing the passion for technology that got you started in the first place. In this presentation, I'll talk about what automation is, and how to approach implementing it in the context of IT Operations. Ned will discuss keys to success in the long term and include practical real-world examples. Ge...
Dion Hinchcliffe is an internationally recognized digital expert, bestselling book author, frequent keynote speaker, analyst, futurist, and transformation expert based in Washington, DC. He is currently Chief Strategy Officer at the industry-leading digital strategy and online community solutions firm, 7Summits.
"NetApp's vision is how we help organizations manage data - delivering the right data in the right place, in the right time, to the people who need it, and doing it agnostic to what the platform is," explained Josh Atwell, Developer Advocate for NetApp, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
Bill Schmarzo, author of "Big Data: Understanding How Data Powers Big Business" and "Big Data MBA: Driving Business Strategies with Data Science," is responsible for setting the strategy and defining the Big Data service offerings and capabilities for EMC Global Services Big Data Practice. As the CTO for the Big Data Practice, he is responsible for working with organizations to help them identify where and how to start their big data journeys. He's written several white papers, is an avid blogge...
When building large, cloud-based applications that operate at a high scale, it's important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. "Fly two mistakes high" is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Le...
When talking IoT we often focus on the devices, the sensors, the hardware itself. The new smart appliances, the new smart or self-driving cars (which are amalgamations of many ‘things'). When we are looking at the world of IoT, we should take a step back, look at the big picture. What value are these devices providing. IoT is not about the devices, its about the data consumed and generated. The devices are tools, mechanisms, conduits. This paper discusses the considerations when dealing with the...
Machine learning has taken residence at our cities' cores and now we can finally have "smart cities." Cities are a collection of buildings made to provide the structure and safety necessary for people to function, create and survive. Buildings are a pool of ever-changing performance data from large automated systems such as heating and cooling to the people that live and work within them. Through machine learning, buildings can optimize performance, reduce costs, and improve occupant comfort by ...
"Our strategy is to focus on the hyperscale providers - AWS, Azure, and Google. Over the last year we saw that a lot of developers need to learn how to do their job in the cloud and we see this DevOps movement that we are catering to with our content," stated Alessandro Fasan, Head of Global Sales at Cloud Academy, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
René Bostic is the Technical VP of the IBM Cloud Unit in North America. Enjoying her career with IBM during the modern millennial technological era, she is an expert in cloud computing, DevOps and emerging cloud technologies such as Blockchain. Her strengths and core competencies include a proven record of accomplishments in consensus building at all levels to assess, plan, and implement enterprise and cloud computing solutions. René is a member of the Society of Women Engineers (SWE) and a m...